All In Biotech

Drug Trial Radar · NCT02099240

Patients Response to Early Switch To Oral:Osteomyelitis Study

Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics

Last checked: Nov 19, 2026Latest source record: Apr 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

11

Actual

Start

Mar 6, 2014

Primary completion

Nov 7, 2018

Study completion Nov 7, 2018

Sponsor

Lead sponsor
Julio RamirezAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Louisville
First posted
Mar 28, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.

Conditions

  • Osteomyelitis

Interventions

  • oral antibioticsDrug

    intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type

  • intravenous antibioticsProcedure

    intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical FailuresTime frame: 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Louisville

    Louisville, Kentucky

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.